{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.9","upperLimit":"92.2","value":"73.33"},{"groupId":"OG001","lowerLimit":"38.4","upperLimit":"88.2","value":"66.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Complete Response (CR) rate to panobinostat maintenance therapy after autologous HCT. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \\< 5% plasma cells in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG000","title":"Cohort A: Maintenance Therapy"},{"description":"Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG001","title":"Cohort B: Maintenance Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"percentage"}